Cell Derived Extracellular Vesicles for the Treatment of Diseases

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a method to produce extracellular vesicles (EVs), specifically exosomes, from tumor cells or other biological cells that have been stimulated with ligands (such as certain RNA or DNA molecules) that activate innate immunity receptors (like RIG-I, MDA5, or cGAS). These EVs are harvested and can be formulated into pharmaceutical compositions. The key innovation is that these EVs display anti-tumor, anti-infective, and immune-stimulatory activities, making them effective for treating cancer or viral diseases by enhancing the body's immune response against tumors or infections.

Use CasesContent extracted from patent full text and abstract with AI.

• Development of new cancer immunotherapies using exosomes to activate natural killer (NK) cells and T-cells.
• Creation of personalized cancer vaccines, where exosomes derived from a patient's own tumor cells are used to stimulate their immune system.
• Design of new antiviral therapies, with exosomes derived from healthy immune or fibroblast cells to fight viral infections.
• Incorporation of EVs into combined therapies to boost immune responses when used with other immunomodulatory drugs.
• Topical or systemic administration of EV-based drugs for treatment of various cancers (melanoma, brain, breast, colon, etc.) or infectious diseases.

BenefitsContent extracted from patent full text and abstract with AI.

• EVs produced by this method can strongly activate key immune cells such as NK cells and dendritic cells, leading to enhanced anti-tumor responses.
• Capable of delivering both immune-stimulatory molecules (ligands) and tumor or viral antigens in one package, leading to robust and specific immune activation.
• Production method allows for both autologous (self-derived) and allogeneic (donor-derived) therapies, offering personalized or off-the-shelf options.
• Potential to induce both innate and adaptive immune responses, for broader and longer-lasting protection or therapy.
• Improved safety profile compared to live or attenuated cell therapies, with lower risk of adverse reactions.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention pertains to extracellular vesicles (exosomes) that are produced by culturing tumor cells in the presence of various ligands or activators of innate immunity receptors and subsequently isolating and purifying the vesicles in the culture supernatant. The invention provides also pharmaceutical compositions comprising the inventive exosomes. The exosomes of the invention are provided as medicaments for example in the treatment of cancer diseases.